ClinicalTrials.gg
CompletedNCT01644175Updated Nov 6, 2015Results posted

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

A Phase 3 interventional study of Placebo (for alirocumab) and Alirocumab in Hypercholesterolemia, sponsored by Sanofi. Completed at 76 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-06.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
13th of 43
316 · median 107
Started
2012
with 11 others
Phase 3
20 of 43
none open now
Registered
14th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 13th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).

Primary Objective of the study:

  • To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT) in comparison with placebo after 24 weeks of treatment in high cardiovascular (CV) risk participants with hypercholesterolemia

Secondary Objectives:

  • To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points
  • To evaluate the effect of alirocumab on other lipid parameters
  • To evaluate the safety and tolerability of alirocumab
Read the detailed description

The maximum study duration was 62 weeks per participant, including a 2-week screening period, 52-week randomized treatment period, and 8-week follow-up period.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who were not adequately controlled with a maximally tolerated daily dose of statin with or without other LMT, both at stable dose for at least 4 weeks to 6 weeks prior to screening (Week -2)

Exclusion criteria

Exclusion criteria:

  • Age \<18 or legal age of adulthood, whichever was greater
  • Participants without established CHD or CHD risk equivalent
  • LDL-C \<70 mg/dL (\<1.81 mmol/L) and participants with a history of documented cardiovascular disease
  • LDL-C \<100 mg/dL (\<2.59 mmol/L) and participants without a history of documented cardiovascular disease
  • Not on a stable dose of LMT (including statin) for at least 4 weeks and/or fenofibrate for at least 6 weeks, as applicable, prior to the screening visit (Week -2) and from screening to randomization
  • Fasting serum triglycerides > 400 mg/dL (>4.52 mmol/L)

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
316 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.

    Drug: Placebo (for alirocumab) · Drug: Lipid-Modifying Therapy (LMT)

  • Experimental
    Alirocumab

    Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.

    Drug: Alirocumab · Drug: Lipid-Modifying Therapy (LMT)

Interventions

  • DrugPlacebo (for alirocumab)

    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).

  • Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).

    Also known as: SAR236553, REGN727

  • Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

    Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

    Time frame: From Baseline to Week 52

  2. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  4. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From baseline to Week 52

  5. Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  6. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  7. Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  9. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  11. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  12. Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

    Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  13. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: Up to Week 52

  14. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis

    Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

    Time frame: Up to Week 52

  15. Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: From baseline to Week 52

  16. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  17. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from multiple imputation approach followed be robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  18. Percent Change From Baseline in Apolipoprotein A-1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  19. Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  20. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  21. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  22. Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

07

Results

Posted Nov 6, 2015

Participant flow

The study was conducted at 76 centers in the United States of America. Overall, 640 participants were screened between July 2012 and February 2013, 324 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlacebo Q2WAlirocumab 75/150 mg Q2W
Started107209
Treated107207
Completed75156
Not completed3253
Withdrew: Randomized but not treated02
Withdrew: Adverse event813
Withdrew: Death12
Withdrew: Poor compliance to protocol910
Withdrew: Physician decision12
Withdrew: Participant moved12
Withdrew: Consent withdrawn by participant34
Withdrew: Related to autoinjector administration21
Withdrew: Last visit outside protocol visit window411
Withdrew: Selection criteria finally not met01
Withdrew: Site closure22
Withdrew: Lost to follow-up10
Withdrew: Other than specified above03

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis-2.3 ± 2.7-48.2 ± 1.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -45.9 · 95% CI -52.5 to -39.3Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis-0.8 ± 2.6-50.7 ± 1.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance was ≤ 0.05.) · Ls mean difference: -49.9 · 95% CI -56.2 to -43.6Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis1.1 ± 2.5-46.3 ± 1.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -47.4 · 95% CI -53.6 to -41.3Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis1.7 ± 2.5-47.6 ± 1.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -49.3 · 95% CI -55.3 to -43.3Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis-0.9 ± 2.3-36.7 ± 1.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -35.8 · 95% CI -41.3 to -30.3Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis-0.4 ± 2.3-37.9 ± 1.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤0.05.) · Ls mean difference: -37.5 · 95% CI -43.0 to -32.0Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis-1.6 ± 2.5-39.1 ± 1.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -37.5 · 95% CI -43.5 to -31.4Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis-0.5 ± 2.5-40.9 ± 1.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -40.4 · 95% CI -46.4 to -34.4Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis-2.9 ± 1.8-27.9 ± 1.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.0 · 95% CI -29.3 to -20.7Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis3.4 ± 2.3-34.8 ± 1.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -38.2 · 95% CI -43.7 to -32.7Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis2.6 ± 2.6-37.4 ± 1.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -40.1 · 95% CI -46.2 to -33.9Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis0.9 ± 2.0-25.4 ± 1.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -26.4 · 95% CI -31.1 to -21.7Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis0.5 ± 3.6-42.5 ± 2.5
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -43.0 · 95% CI -51.6 to -34.3Alirocumab vs. placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 75/150 mg Q2W
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis9.075.0
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 38.5 · 95% CI 16.5 to 89.8Alirocumab vs. placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis

Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 75/150 mg Q2W
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis8.077.5
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05) · Odds ratio (or): 50.0 · 95% CI 20.6 to 121.0Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
From baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis-5.9 ± 2.8-20.5 ± 2.0
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -14.6 · 95% CI -21.3 to -7.9Alirocumab vs. placebo
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis-3.8 ± 1.53.5 ± 1.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Mixed Models Analysis · p = 0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: 7.3 · 95% CI 3.6 to 11.0Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed be robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis-5.4 ± 3.2-6.0 ± 2.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 75/150 mg Q2W · Regression, Robust · p = 0.8699 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -0.6 · 95% CI -8.3 to 7.0Alirocumab vs. placebo
SecondaryPercent Change From Baseline in Apolipoprotein A-1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Apolipoprotein A-1 at Week 24 - ITT Analysis-2.5 ± 1.23.3 ± 0.9
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis0.0 ± 2.7-19.7 ± 1.9
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis-2.4 ± 1.46.7 ± 1.0
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis3.0 ± 2.9-11.3 ± 2.0
SecondaryPercent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75/150 mg Q2W
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis-1.8 ± 1.33.8 ± 0.9

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 60 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—14/107 (13.1%)31/107 (29%)
Alirocumab 75 /up to 150 mg Q2W—26/207 (12.6%)72/207 (34.8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventPlacebo Q2WAlirocumab 75 /up to 150 mg Q2W
Non-cardiac chest painGeneral disorders3/1070/207
Coronary artery diseaseCardiac disorders0/1072/207
Acute myocardial infarctionCardiac disorders0/1072/207
AsthmaRespiratory, thoracic and mediastinal disorders0/1072/207
GastroenteritisInfections and infestations1/1070/207
Clostridium difficile infectionInfections and infestations1/1070/207
Wound infectionInfections and infestations1/1070/207
Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1070/207
Chronic myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1070/207
Oesophageal adenocarcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1070/207
Most frequent other events
Most frequent other events
EventPlacebo Q2WAlirocumab 75 /up to 150 mg Q2W
Upper respiratory tract infectionInfections and infestations11/10716/207
ArthralgiaMusculoskeletal and connective tissue disorders8/1078/207
NasopharyngitisInfections and infestations5/10715/207
Urinary tract infectionInfections and infestations4/10713/207
DizzinessNervous system disorders6/10711/207
SinusitisInfections and infestations4/10711/207
Injection site reactionGeneral disorders3/10711/207

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Q2WAlirocumab 75/150 mg Q2WTotal
Mean63.0 ± 8.863.0 ± 9.563.0 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WAlirocumab 75/150 mg Q2WTotal
Female3078108
Male77131208
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Placebo Q2WAlirocumab 75/150 mg Q2WTotal
Mean2.746 ± 0.9152.595 ± 0.7642.646 ± 0.820
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Placebo Q2WAlirocumab 75/150 mg Q2WTotal
Mean106.0 ± 35.3100.2 ± 29.5102.2 ± 31.6
08

Study locations

76 sites
  • Investigational Site Number 840857
    Birmingham, Alabama 35209, United States
  • Investigational Site Number 840891
    Mobile, Alabama 36693, United States
  • Investigational Site Number 840876
    Montgomery, Alabama 36109, United States
  • Investigational Site Number 840865
    Glendale, Arizona 85306, United States
  • Investigational Site Number 840826
    Jonesboro, Arkansas 72401, United States
  • Investigational Site Number 840870
    Burbank, California 91505, United States
  • Investigational Site Number 840851
    Los Angeles, California 90057, United States
  • Investigational Site Number 840845
    Los Gatos, California 95032, United States
  • Investigational Site Number 840844
    Sacramento, California 95823, United States
  • Investigational Site Number 840801
    San Jose, California 95116, United States
  • Investigational Site Number 840886
    Tarzana, California 91356, United States
  • Investigational Site Number 840862
    Torrance, California 90505, United States
  • Investigational Site Number 840893
    Vista, California 92083, United States
  • Investigational Site Number 840867
    Boca Raton, Florida 33432, United States
  • Investigational Site Number 840884
    Boynton Beach, Florida 33472, United States
  • Investigational Site Number 840836
    Clearwater, Florida 33761, United States
  • Investigational Site Number 840866
    Coral Gables, Florida 33134, United States
  • Investigational Site Number 840895
    Ft. Lauderdale, Florida 33308-4311, United States
  • Investigational Site Number 840820
    Hialeah, Florida, United States
  • Investigational Site Number 840805
    Miami, Florida 33143, United States
  • Investigational Site Number 840811
    Oviedo, Florida 32765, United States
  • Investigational Site Number 840881
    Port Orange, Florida 32127, United States
  • Investigational Site Number 840816
    West Palm Beach, Florida, United States
  • Investigational Site Number 840850
    Columbus, Georgia 31904, United States
  • Investigational Site Number 840840
    Eagle, Idaho, United States
  • Investigational Site Number 840842
    Chicago, Illinois 60611, United States
  • Investigational Site Number 840898
    Evanston, Illinois 60201, United States
  • Investigational Site Number 840847
    Morton, Illinois 61550, United States
  • Investigational Site Number 840896
    Indianapolis, Indiana 46260, United States
  • Investigational Site Number 840894
    Michigan City, Indiana 46360, United States
  • Investigational Site Number 840838
    Mishawaka, Indiana 46545, United States
  • Investigational Site Number 840823
    Paducah, Kentucky 42003, United States
  • Investigational Site Number 840858
    Eunice, Louisiana 70535, United States
  • Investigational Site Number 840802
    New Orleans, Louisiana 70119, United States
  • Investigational Site Number 840855
    Salisbury, Massachusetts 01952, United States
  • Investigational Site Number 840890
    Battle Creek, Michigan 49015, United States
  • Investigational Site Number 840832
    Southfield, Michigan 48034, United States
  • Investigational Site Number 840839
    Edina, Minnesota 55435, United States
  • Investigational Site Number 840888
    Minneapolis, Minnesota 55455, United States
  • Investigational Site Number 840837
    Port Gibson, Mississippi 39150, United States
  • Investigational Site Number 840814
    Jefferson City, Missouri 65109, United States
  • Investigational Site Number 840833
    Sparks, Nevada, United States
  • Investigational Site Number 840817
    Newington, New Hampshire 3801, United States
  • Investigational Site Number 840853
    New Windsor, New York 12553, United States
  • Investigational Site Number 840822
    Rochester, New York 14609, United States
  • Investigational Site Number 840824
    Cary, North Carolina, United States
  • Investigational Site Number 840880
    Smithfield, North Carolina, United States
  • Investigational Site Number 840502
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site Number 840852
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site Number 840846
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840899
    Cincinnati, Ohio 45245, United States
  • Investigational Site Number 840831
    Columbus, Ohio 43231, United States
  • Investigational Site Number 840860
    Kettering, Ohio 45429, United States
  • Investigational Site Number 840809
    Willoughby Hills, Ohio 44094, United States
  • Investigational Site Number 840818
    Norman, Oklahoma 73069, United States
  • Investigational Site Number 840812
    Eugene, Oregon 97404, United States
  • Investigational Site Number 840803
    Downington, Pennsylvania 19335, United States
  • Investigational Site Number 840869
    Philadelphia, Pennsylvania 19146, United States
  • Investigational Site Number 840825
    Pittsburgh, Pennsylvania 15206, United States
  • Investigational Site Number 840872
    Anderson, South Carolina 29621, United States
  • Investigational Site Number 840885
    Charleston, South Carolina 29407, United States
  • Investigational Site Number 840813
    Greer, South Carolina 29651, United States
  • Investigational Site Number 840827
    Mt. Pleasant, South Carolina 29464, United States
  • Investigational Site Number 840868
    Corpus Christi, Texas 78404, United States
  • Investigational Site Number 840877
    Houston, Texas 77070, United States
  • Investigational Site Number 840841
    Houston, Texas 77072, United States
  • Investigational Site Number 840830
    San Antonio, Texas 78224, United States
  • Investigational Site Number 840854
    San Antonio, Texas 78229, United States
  • Investigational Site Number 840883
    San Antonio, Texas 78258, United States
  • Investigational Site Number 840889
    Tomball, Texas 77375, United States
  • Investigational Site Number 840878
    Bountiful, Utah 84010, United States
  • Investigational Site Number 840819
    Orem, Utah 84058, United States
  • Investigational Site Number 840863
    Salt Lake City, Utah 84102, United States
  • Investigational Site Number 840804
    Manassas, Virginia 20110, United States
  • Investigational Site Number 840882
    Norfolk, Virginia 23507, United States
  • Investigational Site Number 840810
    Weber City, Virginia 24290, United States
09

References and documents

Publications

  • Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ, Lorenzato C, Pordy R, Chaudhari U. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord. 2014 Sep 20;14:121. doi: 10.1186/1471-2261-14-121. PubMed 25240705 ↗
  • Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015 Jun;169(6):906-915.e13. doi: 10.1016/j.ahj.2015.03.004. Epub 2015 Mar 13. PubMed 26027630 ↗
  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 7 months after primary completion. A results delay was requested in Feb 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2012
First posted
Jul 18, 2012
Start
Jul 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results delay requested
Feb 9, 2015
Results first posted
Nov 6, 2015
Last update
Nov 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01644175
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 18, 2012
Start date
Jul 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Nov 6, 2015
Last update
Nov 6, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion